ProMIS Neurosciences Inc. · NASDAQ:PMN

ProMIS Neurosciences — Investor Presentation (November 2026)

31 slides from ProMIS Neurosciences's investor presentation, Nov 12, 2026

  1. Slide 1: Targeting underlying causes of neurodegenerative diseases

    Targeting underlying causes of neurodegenerative diseases

  2. Slide 2: Forward-Looking Statements & Disclaimers

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential L E G A L D I S C L O S U R E S Forward-Looking Statements & Disclaimers This slide deck may contain certain forward-looking information and “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Se

  3. Slide 3: Who we are: clinical-stage biotech targeting misfolded proteins

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential W H O W E A R E 3 A clinical-stage biotech targeting the misfolded proteins that drive neurodegenerative disease Our pipeline of antibodies and vaccines are designed to selectively target the specific, disease-causing misfolded forms of pro

  4. Slide 4: The problem: Alzheimer's scale

    T H E P R O B L E M 7.4 million Americans are living with Alzheimer’s today, and that number could nearly double to 13.8M by 2060 1 in 9 Americans age 65 and older has Alzheimer’s Each one is a parent, a spouse or a friend losing memory, independence and the ability to recognize the people they love

  5. Slide 5: Anti-amyloid plaque therapies sell ~$1.4B a year despite safety risks

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Anti-amyloid plaque therapies already sell ~$1.4B a year despite significant safety risks and a boxed warning 5 Clinical Benefit (CDR-SB) Boxed Warning: ARIA Annual Sales Ests. (1) Leqembi (lecanemab) Approved 2023 Adjusted Mean Change from

  6. Slide 6: ~95% of eligible U.S. patients remain untreated

    An estimated ~95% of eligible U.S. patients remain untreated, facing safety, access and cost barriers M A R K E T O P P O R T U N I T Y 6 Market opportunity ~1.26M are early-stage and label-eligible today(2) ~95% untreated (~1.2M patients) ~5% treated (~63K patients)(2) How a Top obstacles to curren

  7. Slide 7: Lead Clinical Candidate PMN310 in Alzheimer's Disease

    Lead Clinical Candidate PMN310 in Alzheimer’s Disease Selectivity for Toxic Aβ Oligomers

  8. Slide 8: Neutralizing toxic AβOs upstream can reduce downstream damage

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Neutralizing toxic AβOs upstream can reduce downstream damage 8 1.The Amyloid Cascade Hypothesis. Castellani, Rudy J. et al. The American Journal of Pathology, Volume 195, Issue 11, Nov 2025 2.Cline EN, et al. The Amyloid-β Oligomer Hypothe

  9. Slide 9: Toxic Aβ oligomers: low abundance, high toxicity, the target of PMN310

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Toxic Aβ oligomers: low abundance, high toxicity, the target of PMN310 in Alzheimer’s disease 9 ILLUSTRATIVE RELATIVE ABUNDANCE OF Aβ SPECIES1 1. 1. Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins:

  10. Slide 10: EpiSelect computational platform for selective antibodies

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential EpiSelectTM computational platform allows for the generation of antibodies selective for toxic misfolded proteins 10 D I S C O V E R Y P L A T F O R M Normal protein (monomers) Misfolds Toxic oligomer Conformational epitope exposed EpiSelec

  11. Slide 11: PMN310 is the only IgG1 mAb designed to solely target toxic Aβ oligomers

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential PMN310 is the only IgG1 mAb designed to solely target toxic amyloid-beta (Aβ) oligomers PMN310 (ProMIS) Phase 1b ongoing Lecanemab (Eisai) Approved Donanemab (Eli Lilly) Approved Sabirnetug (Acumen) Phase 2 Target binding Plaque binding is

  12. Slide 12: PMN310 had undetectable plaque binding

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Plaque detection (no mAb) Amylo-Glo Staining with mAb Staining with mAb Isotype negative controls Test antibodies (fluorescence) (chromogenic) PMN310 was the only mAb tested with undetectable plaque binding through fluorescent and chromogen

  13. Slide 13: Phase 1a SAD study met all objectives

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Healthy volunteers Randomized 3:1, PMN310:Placebo (N=8 per cohort) First subject dosed Nov. 2023 Dose 2.5 mg/kg (N = 6:2) Dose 5 mg/kg (N = 6:2) Dose 10 mg/kg (N = 6:2) Dose 20 mg/kg (N = 6:2) Dose 40 mg/kg (N = 6:2) PMN310 Placebo-Controll

  14. Slide 14: PMN310 reduced Aβ oligomers in CSF in Phase 1a

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential T A R G E T E N G A G E M E N T PMN310 reduced Aβ oligomers in CSF in Phase 1a, measured directly by the sFIDA assay What it measures Aβ oligomer particles in CSF, the target of PMN310 How it works • Captures oligomers and detects them with

  15. Slide 15: Dose-dependent reduction in CSF Aβ oligomer particles

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential A A I C 2 0 2 6 · P H A S E 1 a T A R G E T E N G A G E M E N T PMN310 produced a dose-dependent reduction in CSF Aβ oligomer particles Day 3 post-dose Day 29 post-dose First human evidence of Aβ oligomer target engagement by PMN310 • Relat

  16. Slide 16: PRECISE-AD Interim Analysis Results

    16 PRECISE-AD Interim Analysis Results Presented July 28, 2026 1 Demographics and Study Design 2 Safety Results 3 Biomarker Trends

  17. Slide 17: PRECISE-AD: Phase 1b with FDA Fast Track

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential PRECISE-AD: Phase 1b with FDA Fast Track Randomized, double-blind, placebo-controlled multiple ascending dose study of PMN310 in early AD 17 T R I A L D E S I G N STUDY DESIGN · STAGGERED COHORTS · 12 MONTHS EACH 6-month interim blinded 12-

  18. Slide 18: PRECISE-AD enrolled a representative AD population

    T R I A L D E M O G R A P H I C S PRECISE-AD Enrolled a Representative AD Population, Including the Highest ARIA-Risk Patients WHY APOE4 MATTERS ✓ Representative population, including highest ARIA-risk patients Treatment options may open for ~15% of AD patients who are APOE4 homozygotes, the group c

  19. Slide 19: Favorable safety data across key measures

    I N T E R I M S A F E T Y · 6 - M O N T H B L I N D E D Favorable Safety Data, Observed Across Key Measures 6-month blinded interim · N = 144 dosed, 136 safety-evaluable · a representative population 0.0% ARIA-E The most severe treatment-driven form of ARIA No treatment-related serious AEs Across al

  20. Slide 20: Cumulative ARIA-E over time: zero edema in first 6 months

    T I M E - M A T C H E D S A F E T Y Cumulative ARIA-E Over Time: Zero Edema Observed in First 6 Months ARIA-E (the most serious ARIA type) has been observed to occur almost entirely in the first six months of dosing. Comparator ARIA-E plateaus after the first few months; rates are time-matched to pu

  21. Slide 21: Cumulative total ARIA over time

    T I M E - M A T C H E D S A F E T Y Cumulative Total ARIA Over Time: Blinded PRECISE-AD Data Tracks the Placebo Range Reported in Other Trials Approved anti-amyloids accrue ARIA steeply in the first months of dosing, with 90%+ of ARIA-E occurring in the first 6 months. Comparator rates are time-matc

  22. Slide 22: PRECISE-AD Interim Biomarker Results

    22 PRECISE-AD Interim Biomarker Results

  23. Slide 23: Two tau biomarkers reported

    B I O M A R K E R S R E P O R T E D Two tau biomarkers reported, both expected to rise without treatment 23 Plasma pTau217 BLOOD-BASED W HAT I T M EASURES Disease progression: a downstream marker of amyloid-positive AD pathology and tau pathway activation. I N UNTREATED PATI ENTS In untreated (place

  24. Slide 24: Plasma pTau217 declined through Day 169

    6 - M O N T H B L I N D E D A N A L Y S I S · P L A S M A PRECISE-AD INTERIM RESULTS: Plasma pTau217 declined steadily through Day 169 PRECISE-AD Mean % change from baseline over time -25 -20 -15 -10 -5 0 5 0 29 85 141 169 % change from baseline Study day Linear trend PRECISE-AD patients with a Day-

  25. Slide 25: CSF MTBR-tau243 declined through Day 169

    6 - M O N T H B L I N D E D A N A L Y S I S · C S F PRECISE-AD INTERIM RESULTS: CSF MTBR-tau243 declined through Day 169 PRECISE-AD Mean % change, screen → Day 169 -25 -20 -15 -10 -5 0 5 Screen Day 169 % change from baseline Timepoint PRECISE-AD: Patients with a Day-169 decline 62.5% 37.5% 0 20 40 6

  26. Slide 26: Conclusion: a differentiated, precision approach to Alzheimer's

    C O N C L U S I O N A Differentiated, Precision Approach to Alzheimer’s — With a Clear Path Forward PRECISE-AD’s blinded interim analysis shows favorable safety data and early, mechanism-consistent biomarker signals, supporting a differentiated approach for patients underserved by approved anti-amyl

  27. Slide 27: Topline in Q1 2027 and the Path Forward

    27 Topline in Q1 2027 and the Path Forward

  28. Slide 28: Q1 2027 topline data target scenario

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential T O P L I N E · Q 1 2 0 2 7 Q1 2027 topline data aims to show a material shift in benefit-risk 28 Target scenario reflect management’s view on possible safety and directional efficacy signals and is not based on any review of clinical data

  29. Slide 29: 2026 Strategic Priorities

    Copyright 2026, ProMIS Neurosciences Inc., Non-confidential Q 1 Q 2 Q 3 Q 4 PRECISE-AD Phase 1b PMN310 in early AD — execute + complete Phase 1b Execution Subcutaneous PMN310 Accelerated SC formulation development SC formulation + PK/PD Registrational study prep PMN310 pivotal trial readiness Site a

  30. Slide 30: Why ProMIS

    W H Y P R O M I S Early PRECISE-AD signals support PMN310’s differentiated profile S U M M A R Y A potentially favorable and differentiated benefit-risk profile 12-month PRECISE-AD topline in Q1 2027, with cash runway through 2027 30 01 Novel precision targeting EpiSelect discovery platform, with a

  31. Slide 31: For further information, contact

    NASDAQ: PMN For further information, contact: info@promisneurosciences.com

ProMIS Neurosciences — Investor Presentation (November 2026) on 6ix